Business
Cardiff Oncology Reports Third Quarter 2021 Results and Provides Business Updates
- Announced updated clinical data from lead KRAS-mutated metastatic colorectal cancer program showing an objective response rate and median progression free
About this update from Cardiff Oncology, Inc.
[{"type":"text","content":"- Announced updated clinical data from lead KRAS-mutated metastatic colorectal cancer program showing an objective response rate and median progression free survival that substantially exceed those seen in historical control trials\n - Strengthened management team with the appointments of Katherine L. Ruffner, M.D., as CMO and James E. Levine as CFO\n - Cash, cash equivalents, and short-term investments of approximately $134 million as of September 30, 2021\n\n\nSAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced recent company highlights and financial results for the third quarter ended September 30, 2021. \n\n \n \n \n \n \n \n\n \n\"During the third quarter, the data we released from our Phase 1b/2 KRAS-mutated metastatic colorectal cancer trial showed meaningful improvements in treatment response and durability relative to historical controls,\" said Mark Erlander, Ph.D., chief executive officer of Cardiff Oncology. \"With radiographic responses achieved across multiple KRAS mutation variants, we believe these findings differentiate onvansertib from agents targeting individual KRAS mutations such as G12C.\"\nDr. Erlander added, \"Beyond our KRAS-focused programs, we also continue to leverage onvansertib's broadly applicable mechanism of action to advance its development as a platform molecule. By targeting PLK1, onvansertib inhibits DNA repair and processes that promote mitosis, positioning it to combine synergistically with a range of anti-cancer agents and potentially improve outcomes across a broad array of difficult-to-treat indications.\"\nProgram highlights for the quarter ended September 30, 2021, include:\nKRAS-mutated Metastatic Colorectal Cancer (mCRC) Program:\nAnnounced new data from Phase 1b/2 trial evaluating onvansertib plus FOLFIRI/bevacizumab continuing to show robust objective response rate and progression-free survival\nThe data were presented as part of a key opinion leader webinar and showed that trial participants treated with onvansertib plus standard-of-care FOLFIRI/bevacizumab had an objective response ...